The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder (Q36653650)

15 August 2017

1 reference

title

The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder (English)

1 reference

15 August 2017

8

Hans-Dieter Volk

1 reference

15 August 2017

Sandra Philipp

1

1 reference

15 August 2017

Kerstin Wolk

2

1 reference

15 August 2017

Stephanie Kreutzer

3

1 reference

15 August 2017

Elizabeth Wallace

4

1 reference

15 August 2017

Nina Ludwig

5

1 reference

15 August 2017

Joachim Roewert

6

1 reference

15 August 2017

Conny Höflich

7

1 reference

15 August 2017

Wolfram Sterry

9

1 reference

15 August 2017

Robert Sabat

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Therapeutic Targets

15 August 2017

1 reference

15 August 2017

10

1 reference

15 August 2017

6

1 reference

15 August 2017

817-831

1 reference

The prevalence of psoriasis in the world

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Epidemiology of psoriasis. Review and the German perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Getting under the skin: the immunogenetics of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Psoriasis--epidemiology and clinical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Epidemiology of psoriatic arthritis in the population of the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Inhibitory effect of cyclosporin A on antigen and alloantigen presenting capacity of human epidermal Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Dimethylfumarate for psoriasis: more than a dietary curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Immunopathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Alefacept therapy produces remission for patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Efalizumab: a review of events reported during clinical trials and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Efalizumab in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Update on the mechanisms and efficacy of biological therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The long-term efficacy and safety of new biological therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Resident skin-specific gammadelta T cells provide local, nonredundant regulation of cutaneous inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Keratinocyte growth regulation by the products of immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Interleukin 20: discovery, receptor identification, and role in epidermal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The cornified envelope: a model of cell death in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

IL-22 increases the innate immunity of tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Interleukin-10 and related cytokines and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

The expression of legumain, an asparaginyl endopeptidase that controls antigen processing, is reduced in endotoxin-tolerant monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

A randomized trial of etanercept as monotherapy for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Effects of rIFN Alpha, Beta, and Gamma on the Morphology, Proliferation, and Cell Surface Antigen Expression of Human Dermal Microvascular Endothelial Cells In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

Cytokine profiles during infliximab monotherapy in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.817

10.1517/14728222.10.6.817

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference